RxDoctor Payments DataLook up a doctor →

John Kingrey, MD

Pulmonary Disease · Oklahoma City, OKNPI 1689863953

Payments from drug & device makers

$2,412,652in general payments, 2019–2025

Across 740 payments — averaging $3260.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.3M
  • United Therapeutics Corporation$813K
  • Actelion Pharmaceuticals US, Inc.$164K
  • Janssen Research & Development, LLC$75K
  • Actelion Pharmaceuticals, Ltd$40K
  • Bayer$25K
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$55,23617%
  • Speaking & faculty fees$240,63872%
  • Travel & lodging$17,6435%
  • Food & beverage$12,0834%
  • Education$6,5772%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,412,652 in reported general payments places this provider in the 95th percentile of 133 pulmonary disease providers in Oklahoma.

See all pulmonary disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$108,666
Medicare patients
339
Services billed
1,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan800$9,973,163
UptraviSelexipag351$7,728,354
Orenitram ErTreprostinil Diolamine378$5,262,015
AdempasRiociguat376$5,113,697
Tyvaso DpiTreprostinil205$4,888,179
WinrevairSotatercept-Csrk66$1,345,059
OfevNintedanib Esylate67$983,244
Ambrisentan189$486,157
LetairisAmbrisentan17$218,745
TracleerBosentan14$178,559
Tadalafil476$153,463
Prolastin CAlpha-1-Proteinase Inhibitor12$153,208
EliquisApixaban173$137,154
Bosentan36$128,630
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$66,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer, Bosentan$164,373$18,008,7051,201 claims
BayerAdempas$25,419$5,113,697376 claims
MerckWinrevair$1,293,276$1,345,05966 claims
Boehringer IngelheimOfev, Jardiance$351$1,020,311120 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$40$106,783164 claims
SandozEnoxaparin Sodium$215$2,03214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 pulmonary disease providers in Oklahoma.

Other pulmonary disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →